Strategic Wealth Advisors Group LLC bought a new stake in UnitedHealth Group Inc (NYSE:UNH) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 10,896 shares of the healthcare conglomerate’s stock, valued at approximately $2,331,000.
A number of other hedge funds have also recently added to or reduced their stakes in UNH. Aevitas Wealth Management Inc. acquired a new stake in shares of UnitedHealth Group in the 4th quarter valued at approximately $102,000. Exane Derivatives boosted its stake in shares of UnitedHealth Group by 15,333.3% in the 4th quarter. Exane Derivatives now owns 463 shares of the healthcare conglomerate’s stock valued at $102,000 after purchasing an additional 460 shares in the last quarter. Pathstone Family Office LLC acquired a new stake in shares of UnitedHealth Group in the 4th quarter valued at approximately $129,000. Trustcore Financial Services LLC acquired a new stake in shares of UnitedHealth Group in the 4th quarter valued at approximately $133,000. Finally, Baystate Wealth Management LLC boosted its stake in shares of UnitedHealth Group by 64.9% in the 4th quarter. Baystate Wealth Management LLC now owns 762 shares of the healthcare conglomerate’s stock valued at $186,000 after purchasing an additional 300 shares in the last quarter. 85.10% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms have recently weighed in on UNH. Zacks Investment Research downgraded shares of UnitedHealth Group from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. Piper Jaffray Companies restated a “buy” rating and issued a $270.00 price target on shares of UnitedHealth Group in a research note on Wednesday, April 18th. Credit Suisse Group raised their price target on shares of UnitedHealth Group from $260.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, April 18th. Finally, Oppenheimer raised their price target on shares of UnitedHealth Group from $260.00 to $276.00 and gave the company an “outperform” rating in a research note on Wednesday, April 18th. Two analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $254.66.
In other news, CEO Steven H. Nelson sold 14,233 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The shares were sold at an average price of $230.22, for a total value of $3,276,721.26. Following the transaction, the chief executive officer now owns 18,219 shares in the company, valued at approximately $4,194,378.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard T. Burke sold 10,400 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $229.87, for a total transaction of $2,390,648.00. Following the completion of the transaction, the director now owns 1,781,657 shares in the company, valued at approximately $409,549,494.59. The disclosure for this sale can be found here. Insiders sold a total of 87,019 shares of company stock worth $20,283,033 in the last 90 days. Corporate insiders own 0.87% of the company’s stock.
Shares of NYSE UNH opened at $244.95 on Friday. The company has a market capitalization of $233.26 billion, a PE ratio of 24.32, a PEG ratio of 1.40 and a beta of 0.75. UnitedHealth Group Inc has a 52-week low of $174.92 and a 52-week high of $250.79. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.71 and a current ratio of 0.71.
UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings results on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.91 by $0.13. The firm had revenue of $55.19 billion for the quarter, compared to the consensus estimate of $54.90 billion. UnitedHealth Group had a net margin of 5.41% and a return on equity of 22.06%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.37 EPS. equities research analysts expect that UnitedHealth Group Inc will post 12.61 EPS for the current year.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.